Denavir Related Published Studies
Well-designed clinical trials related to Denavir (Penciclovir)
Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. [2007.11]
Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial. [2002.06]
Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. [2002.03]
A comparison of topical application of penciclovir 1% cream with acyclovir 3% cream for treatment of genital herpes: a randomized, double-blind, multicentre trial. [2000.09]
Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group. [2000.01]
Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. [1999.05]
Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. [1997.05.07]
Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. [1994.01]
Well-designed clinical trials possibly related to Denavir (Penciclovir)
Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. [2009.02]
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. [2006.09]
Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. [2005.10.15]
Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. [2004.04]
Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. [2002.07]
Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. [2000.08]
A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis. [1999.12]
Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. [1998.01.01]
Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. [1997.02.10]
Safety of famciclovir in patients with herpes zoster and genital herpes. [1994.10]
Other research related to Denavir (Penciclovir)
Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection. [2009.04.02]
HPLC method for the determination of penciclovir in human plasma and application to a bioequivalence study. [2008.10]
Formulation design of microemulsion for dermal delivery of penciclovir. [2008.08.06]
Penciclovir cream--improved topical treatment for herpes simplex infections. [2004.09]
Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. [2003.09]
Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis. [2003.04.15]
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. [2003.01]
Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. [2001.09]
Recurrent herpes labialis: efficacy of topical therapy with penciclovir compared with acyclovir (aciclovir). [2001.01]
In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections. [2001.01]
Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice. [2001]
Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs. [2000.01]
Distribution to the skin of penciclovir after oral famciclovir administration in healthy volunteers: comparison of the suction blister technique and cutaneous microdialysis. [1999.07]
Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. [1998.08]
Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. [1998.06]
The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. [1998.02]
Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. [1997.07]
Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo. [1996.08]
The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. [1996.02]
Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. [1993.04]
The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. [1992.05]
The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. [1992]
Other possibly related research studies
Recent clinical experience with famciclovir--a "third generation" nucleoside prodrug. [2004.09]
Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study. [2004.08]
Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster. [2003.08]
Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections. [2003.09]
The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis. [2003.03]
Novel agents and strategies to treat herpes simplex virus infections. [2003.02]
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs. [2002.10]
Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis. [2002.09]
[Genital herpes: epidemiology, transmission, clinic, asymptomatic viral excretion, impact on other sexually transmitted diseases, prevention, and treatment] [2002.04]
Recent developments in herpesvirus therapy. [2001.03]
Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. [2000.06]
Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo. [2000.03]
Clinical and pathological findings of a newly recognized disease of elephants caused by endotheliotropic herpesviruses. [2000.01]
Antiviral agents for non-human immunodeficiency virus infections. [1999.12]
Famciclovir update. Chronic hepatitis B. [1999]
Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes. [1999.01]
Experience with lamivudine against hepatitis B virus. [1997]
New therapeutic approaches to the alphaherpesvirus infections. [1997.02]
Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. [1996.08]
The pharmacological profile of famciclovir. [1996.06]
In vitro evaluation of combination therapies against hepatitis B virus replication. [1996.01]
Pharmacokinetics of new antiherpetic agents. [1995.11]
Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. [1994.12]
Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. [1994.03]
Acyclovir--and beyond. [1994]
Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. [1994]
Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. [1988.03]
[Genital herpes] [2005.09]
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. [2005.06]
Antiviral drugs in current clinical use. [2004.06]
Changing paradigms in dermatology: antivirals in dermatology. [2003.09]
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. [2003.11]
Inhibition of sickling in vitro by three purine-based antiviral agents: an approach to the treatment of sickle cell disease. [2003.09]
Recurrent herpes simplex labialis: selected therapeutic options. [2003.09]
Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. [2003.05]
Current and potential therapies for the treatment of herpes-virus infections. [2003]
Herpes simplex virus resistance to antiviral drugs. [2003.01]
Herpes simplex virus infection. [2002.01]
New treatments for genital herpes. [2002.02]
Viral diseases of the skin: diagnosis and antiviral treatment. [2002]
Famiciclovir therapy (famvir) for herpes simplex and herpes zoster infections. [2001.11]
Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. [2001.11]
Current and potential therapies for the treatment of herpesvirus infections. [2001]
Contact dermatitis from topical antiviral drugs. [2001.05]
Genetic risks of antiviral nucleoside analogues--a survey. [2001.02]
Guanosine analogues as anti-herpesvirus agents. [2000.10]
Novel agents for the therapy of varicella-zoster virus infections. [2000.08]
Antiviral therapy of herpes simplex. [2000.10]
Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models. [2000.10]
Valaciclovir: a review of its use in the management of herpes zoster. [2000.06]
Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. [2000.04]
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. [2000.05]
Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. [2000.01]
[Antiherpetic chemotherapy] [2000.04]
Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation. [1999.08]
Perspectives for the treatment of hepatitis B virus infections. [1999.07]
Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. [1999.02]
New antivirals - mechanism of action and resistance development. [1998.10]
The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. [1998.10]
Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. [1998.11]
Treatment of Herpes simplex virus infections with topical antiviral agents. [1998.07]
|
